A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Medtronic Receives Spine Industry’s First and Only FDA Clearance for Breakthrough Device Indicated for Ligament Augmentation

Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Breakthrough Device designation for its novel LigaPASS™ 2.0 Ligament Augmentation System. LigaPASS™ is the first and only FDA cleared device with indication for ligament augmentation in spine surgery.

Ligament augmentation has been studied for its impact on proximal junctional kyphosis (PJK), a frequent post-operative complication of adult spinal deformity surgery1. While the exact cause is unknown, PJK is thought to involve disruption of spinal ligaments and can affect up to 46% of patients1. The condition can significantly impact a patient’s quality of life.2 The severity of PJK can vary, and some patients may develop a more severe form of the condition called proximal junctional failure (PJF). Patients who develop PJF may develop structural and neurological complications, which increases the need for revision surgery.

“The surgical treatment of adult spinal deformity provides significant clinical benefit to patients but unfortunately many require revision due to early mechanical failure. The most common cause of mechanical failure is proximal junctional kyphosis, “said Christopher Ames, M.D., director of spinal tumor and spinal deformity surgery at UCSF Medical Center in California. “Failure reduction strategies, such as ligament augmentation, are likely to become critical techniques in the treatment of this challenging patient population. In my practice, LigaPASS™ 2.0 helps me meet my goals to reduce revision surgeries with these patients.”

A study of 242 adult spinal deformity cases found patients treated with ligament augmentation had significantly lower PJK and PJF complication rate as follows:

After one year, the reoperation rate for adult spinal deformity patients treated with ligament augmentation was just 3.3% compared to 15.6% of not treated with ligament augmentation.3,4

The ligament augmentation technique aims to reduce the reoperation rate for PJF and its associated costs, which can be more than $50,000 per procedure5,6

The LigaPASS™ 2.0 system can also be paired with the UNiD™ Adaptive Spine Intelligence (ASI) platform. UNiD™ ASI is transforming the standard of care for patient-specific spine surgery by leveraging data science and artificial intelligence to help surgeons plan, execute and analyze their procedures. LigaPASS™ 2.0 system connectors and bands may also be used in conjunction with the CD Horizon™ Solera™ spinal system.

“This clearance and Breakthrough Device designation demonstrates our ongoing commitment to innovation in spine surgery and delivering industry-leading solutions that improve care for patients and improve the experience for surgeons,” said Dan Wolf, vice president and general manager, intelligent Data Solutions at Medtronic.

About LigaPASS™ 2.0 system: The LigaPASS™ ligament augmentation technique provides surgeons the ability to stabilize between vertebrae that are collapsed or are at risk of collapsing in adult spinal deformity patients requiring constructs that may extend from T1 to the pelvis. This innovative surgical procedure aims to compensate for muscle collapse during open posterior surgery and decrease junctional stress at the UIV and adjacent levels through a band lacing technique using LigaPASS™ 2.0 system implants. The LigaPASS™ 2.0 system medial connector is designed to provide additional support to the junction between the instrumented and adjacent non-instrumented levels.

About UNiD™ ASI Platform: The UNiD ASI platform uses a database of thousands of surgical cases to power algorithms that visualize multiple permutations, allowing surgeons to better understand their patient’s alignment before surgery, customize a surgical plan with highly qualified UNiD™ LAB biomedical engineers and use a patient-specific rod industrially bent in the optimal plane to help ensure the goals of the surgery are achieved.

About the CD Horizon™ Solera™ Spinal Systems: These systems help provide immobilization and stabilization of spinal segments. The systems consist of a variety of screws and other implant components that can be rigidly locked into a variety of configurations, with each construct being tailor-made for the patient’s unique anatomy and sagittal alignment needs.

References

Lau, Darryl, et al. “Proximal junctional kyphosis and failure after spinal deformity surgery: a systematic review of the literature as a background to classification development.” Spine 39.25 (2014): 2093-2102.

Lau, Darryl, et al. “The clinical correlation of the Hart-ISSG Proximal Junctional Kyphosis Severity Scale with health-related quality-of-life outcomes and need for revision surgery.” Spine 41.3 (2016): 213-223.

Safaee MM, Deviren V, Dalle Ore CL, Scheer JK, Lau D, Osario J, Nicholls F, Ames CP. Ligament augmentation for prevention of proximal junctional kyphosis and proximal junctional failure in adult spinal deformity. J Neurosurg Spine. 2018 Feb 23

Safaee MM, Haddad AF, Fury M, Maloney PR et al. Reduced proximal junctional failure with ligament augmentation in adult spinal deformity: a series of 242 cases with a minimum 1-year follow-up. J Neurosurg Spine. 2021 Aug 20;1-9.

Theologis, AA, Miller L, Callahan M, et al. Economic Impact of Revision Surgery for Proximal Junctional Failure After Adult Spinal Deformity Surgery: A Cost Analysis of 57 Operations in a 10-year Experience at a Major Deformity Center. Spine (Phila Pa 1976). 2016 Aug 15;41(16):E964-E972.

Safaee MM, Dalle Ore CL, Zygourakis CC, Deviren V, Ames CP. The unreimbursed costs of preventing revision surgery in adult spinal deformity: analysis of cost-effectiveness of proximal junctional failure prevention with ligament augmentation. Neurosurg Focus. 2018 May;44(5):E13.

SourceMedtronic
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy